Biomarin Pharmaceutical Inc
BMRN: XNAS (USA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$78.00 | Pmnjd | Pvylcvks |
BioMarin Earnings: In-Line 2023 Results; Maintaining FVE Despite Lowering Our 2024 Forecast
BioMarin saw 20% year-over-year revenue growth in the fourth quarter as achondroplasia drug Voxzogo continued its strong trajectory, and we're maintaining our $96 fair value estimate. We think BioMarin shares are fairly valued at recent prices, incorporating both Voxzogo's strong potential and BioMarin's improving overall operating margins, but also a disappointing launch for hemophilia A gene therapy Roctavian and unclear potential for the firm's pipeline. We continue to see BioMarin's portfolio and pipeline of rare disease drugs supporting a narrow moat.